相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
Thu Oanh Dang et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Expression of stem cell markers nanog and PSCA in gastric cancer and its significance
Xuanzhong Zhao et al.
ONCOLOGY LETTERS (2016)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma
Kesang Li et al.
ONCOTARGET (2016)
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Jae H. Park et al.
BLOOD (2016)
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Mark B. Geyer et al.
CYTOTHERAPY (2016)
Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma
Ruifen Dong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
Gregory S. Alexander et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Prospects for gene-engineered T cell immunotherapy for solid cancers
Christopher A. Klebanoff et al.
NATURE MEDICINE (2016)
Driving CAR T-cells forward
Hollie J. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
Gregory L. Beatty et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects
Shengmeng Di et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Kaichao Feng et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer
Angel Qin et al.
CANCER MEDICINE (2016)
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Profiling cancer testis antigens in non-small-cell lung cancer
Dijana Djureinovic et al.
JCI INSIGHT (2016)
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein
Haiying Qin et al.
BLOOD (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments
Wei Ye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
Carol O'Hear et al.
HAEMATOLOGICA (2015)
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
Victoria Hillerdal et al.
BMC CANCER (2014)
Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Serena K. Perna et al.
CLINICAL CANCER RESEARCH (2014)
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
Daniel Abate-Daga et al.
HUMAN GENE THERAPY (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Interleukin 15 Provides Relief to CTLs from Regulatory T Cell-Mediated Inhibition: Implications for Adoptive T Cell-Based Therapies for Lymphoma
Serena K. Perna et al.
CLINICAL CANCER RESEARCH (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
PSCA and Oct-4 Expression in the Benign and Malignant Lesions of Gallbladder: Implication for Carcinogenesis, Progression, and Prognosis of Gallbladder Adenocarcinoma
Qiong Zou et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Cellular Immunotherapy for Carcinoma Using Genetically Modified EGFR-Specific T Lymphocytes
Xikun Zhou et al.
NEOPLASIA (2013)
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
De-Gang Song et al.
BLOOD (2012)
MUC1 glycopeptide epitopes predicted by computational glycomics
Wei Song et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
Andreas A. Hombach et al.
ONCOIMMUNOLOGY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer
Dongrong Situ et al.
MEDICAL ONCOLOGY (2011)
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice
John C. Markley et al.
BLOOD (2010)
Clinical Significance of Prostate Stem Cell Antigen Expression in Non-small Cell Lung Cancer
Takeshi Kawaguchi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
V. Hoyos et al.
LEUKEMIA (2010)
Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor
Scott Wilkie et al.
JOURNAL OF IMMUNOLOGY (2008)
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
Tove Olafsen et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism
ZN Gu et al.
CANCER RESEARCH (2005)
A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients
S Matsueda et al.
PROSTATE (2004)
Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer
S Matsueda et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
分享论文
